Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01653132 · ClinicalTrials.gov registry record · Phase 2
Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
A Phase 2 study of Sialorrhea, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01653132 is a Phase 2 study of Sialorrhea that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01653132, a Phase 2 study of Sialorrhea, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted this study to determine whether injections of Xeomin®, a type of botulinum toxin into the glands that produce saliva (one pair just below and in front of the ear and the other just under the jaw line) are safe and effective to treat excessive saliva, or drooling in patients with Parkinson's Disease (PD)/parkinsonism.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Incobotulinum Toxin A
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01653132
The ClinicalTrials.gov registry entry for NCT01653132 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sialorrhea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01653132 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01653132 about?
NCT01653132 is a clinical study titled "Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism". This study is being conducted this study to determine whether injections of Xeomin®, a type of botulinum toxin into the glands that produce saliva (one pair just below and in front of the ear and the other just under the jaw line) are safe and effective to treat excessive saliva, or drooling in pati...
What is the current status of trial NCT01653132?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-03. Estimated completion is 2014-09.
What conditions does trial NCT01653132 study?
This clinical trial studies the following conditions: Sialorrhea.
What interventions are being tested in trial NCT01653132?
The interventions under investigation include: Placebo (DRUG), Incobotulinum Toxin A (DRUG).
Who is sponsoring clinical trial NCT01653132?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01653132 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sialorrhea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.